ZENITH NEGOTIATING THREE-YEAR SUPPLY DEAL WITH SQUIBB
Executive Summary
ZENITH NEGOTIATING THREE-YEAR SUPPLY DEAL WITH SQUIBB for "selected" generic products to be sold under the SquibbMark label, Zenith announced in a June 18 press release. The disclosure was made at the Zenith annual shareholders meeting in Park Ridge, New Jersey, and repeated in the follow up press release. "The agreement is expected to include certain Zenith products that are currently on the market and others for which new drug applications are pending approval from the U.S. FDA," the release states. "The product to be manufactured for the SquibbMark label will be produced by Zenith in conformity with quality assurance and quality control procedures of Squibb, as is the case for any supplier." Zenith's most recent ANDA approvals include three oral cephalosporin products: cephadrine -- Squibb's Velocef and SmithKline's Anspor; cefadroxil -- Bristol-Myers Duricef and Ultracef; and cephalexin -- Lilly's Ceclor.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth